Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12

Eli Lilly and Co (NYSE:LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.The company said internal testing detected a previously unidentified impurity formed when the two substances interact.The drugmaker evaluated compounded products marketed in the U.S. that combine tirzepatide with vitamin B12—also referred to as methylcobalamin, hydroxocobalamin, or cyanocobalamin.Laboratory testing revealed significant levels ...